Sign In
Buy DRW3
Drägerwerk AG & . KGaA Earnings Calls
| Release date | Oct 29, 2025 |
| EPS estimate | - |
| EPS actual | 1.92€ |
| Revenue estimate | 833.1M |
| Revenue actual | 833.3M |
| Revenue Surprise | 0.0240% |
| Release date | Jul 29, 2025 |
| EPS estimate | -0.100€ |
| EPS actual | 0.600€ |
| EPS Surprise | 700.00% |
| Revenue estimate | 730.3M |
| Revenue actual | 779.987M |
| Revenue Surprise | 6.80% |
| Release date | Apr 30, 2025 |
| EPS estimate | - |
| EPS actual | -0.120€ |
| Revenue estimate | 730M |
| Revenue actual | 730.262M |
| Revenue Surprise | 0.0359% |
| Release date | Jan 15, 2025 |
| EPS estimate | - |
| EPS actual | 4.05€ |
| Revenue estimate | - |
| Revenue actual | 1.076B |
Last 4 Quarters for Drägerwerk AG & . KGaA
Below you can see how DRW3.DE performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jan 15, 2025 |
| Price on release | 49.00€ |
| EPS estimate | - |
| EPS actual | 4.05€ |
| Date | Price |
|---|---|
| Jan 09, 2025 | 49.00€ |
| Jan 10, 2025 | 48.80€ |
| Jan 13, 2025 | 47.60€ |
| Jan 14, 2025 | 48.80€ |
| Jan 15, 2025 | 49.00€ |
| Jan 16, 2025 | 53.10€ |
| Jan 17, 2025 | 56.10€ |
| Jan 20, 2025 | 54.80€ |
| Jan 21, 2025 | 55.90€ |
| 4 days before | 0% |
| 4 days after | 14.08% |
| On release day | 8.37% |
| Change in period | 14.08% |
| Release date | Apr 30, 2025 |
| Price on release | 59.60€ |
| EPS estimate | - |
| EPS actual | -0.120€ |
| Date | Price |
|---|---|
| Apr 24, 2025 | 61.10€ |
| Apr 25, 2025 | 61.00€ |
| Apr 28, 2025 | 60.00€ |
| Apr 29, 2025 | 60.50€ |
| Apr 30, 2025 | 59.60€ |
| May 02, 2025 | 60.30€ |
| May 05, 2025 | 60.70€ |
| May 06, 2025 | 60.40€ |
| May 07, 2025 | 62.00€ |
| 4 days before | -2.45% |
| 4 days after | 4.03% |
| On release day | 1.17% |
| Change in period | 1.47% |
| Release date | Jul 29, 2025 |
| Price on release | 69.90€ |
| EPS estimate | -0.100€ |
| EPS actual | 0.600€ |
| EPS surprise | 700.00% |
| Date | Price |
|---|---|
| Jul 23, 2025 | 68.30€ |
| Jul 24, 2025 | 69.30€ |
| Jul 25, 2025 | 69.00€ |
| Jul 28, 2025 | 69.60€ |
| Jul 29, 2025 | 69.90€ |
| Jul 30, 2025 | 71.00€ |
| Jul 31, 2025 | 70.30€ |
| Aug 01, 2025 | 67.90€ |
| Aug 04, 2025 | 67.70€ |
| 4 days before | 2.34% |
| 4 days after | -3.15% |
| On release day | 1.57% |
| Change in period | -0.88% |
| Release date | Oct 29, 2025 |
| Price on release | 71.40€ |
| EPS estimate | - |
| EPS actual | 1.92€ |
| Date | Price |
|---|---|
| Oct 23, 2025 | 77.40€ |
| Oct 24, 2025 | 76.60€ |
| Oct 27, 2025 | 76.30€ |
| Oct 28, 2025 | 75.60€ |
| Oct 29, 2025 | 71.40€ |
| Oct 30, 2025 | 74.30€ |
| Oct 31, 2025 | 73.00€ |
| Nov 03, 2025 | 72.00€ |
| Nov 04, 2025 | 71.40€ |
| 4 days before | -7.75% |
| 4 days after | 0% |
| On release day | 4.06% |
| Change in period | -7.75% |
Drägerwerk AG & . KGaA Earnings Call Transcript Summary of Q3 2025
Key investor takeaways: Dräger delivered a strong first nine months of 2025 with order intake up to ~EUR 2.6bn (9% currency-adjusted) and net sales of ~EUR 2.3bn (+~4% YTD). Q3 was particularly strong (net sales +~10%, EBIT more than doubled to ~EUR 57m, EBIT margin 6.8%). Operating cash flow improved by ~EUR 35m to ~EUR 93m; free cash flow was ~EUR 17m (higher investing outflows vs. prior year due to one-off disposals in 2024 and an investment this year). Management raised its outlook to the upper half of the prior guidance: now expecting net sales growth of 3.0%–5.0% (currency-adjusted) and an EBIT margin of 4.5%–6.5% (EBIT now guided at EUR 10m–18m). Division notes: Medical returned to positive EBIT in Q3 (EUR 11m) as ventilators, anesthesia machines, services and consumables drove demand; Safety remains solid with an EBIT margin ~12.6% in Q3 and ~10% YTD. Financial position is healthy: net financial debt/EBITDA ~0.7, equity ratio ~50%, ROCE improving to 12%. Main headwinds/risks: currency appreciation and tariffs (FX reduced EBIT by roughly EUR 22m year-to-date), some regional softness (notably uneven China demand in Q3), and seasonality/sensitivity around Q4 execution. Management remains focused on execution and proactive FX hedging/price adjustments.
